THE US FDA has announced a
voluntary recall of all products
made by a compounding pharmacy
firm called Ameridose, based in
Westborough, Massachusetts.
The move follows an inspection of
the company’s manufacturing area,
with the FDA’s preliminary findings
having raised concern about “a lack
of sterility assurance” for items
produced at the facility.
Ameridose shares common
management with New England
Compounding Pharmacy, which
was recently linked to an outbreak
of fungal meningitis (PD 10 Oct).
However unlike NECP, the
Ameridose recall is not based on
reports of patients who have
contracted infections as a result of
using the products.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Nov 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Nov 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.